StockNews.AI
NSPR
StockNews.AI
174 days

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

1. InspireMD will release Q4 and full year 2024 results on March 12, 2025. 2. A conference call will follow to discuss financial results and highlights. 3. NSPR focuses on improving carotid stenting with its MicroNet technology. 4. Live earnings call will be accessible via telephone and webcast. 5. The company aims to be a standard in carotid artery treatment.

Earnings
-1.47%Current Return
VS
-0.86%S&P 500
$3.402/26 08:07 AM EDTEvent Start
$3.3502/27 02:49 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings report could influence short-term investor sentiment without definitive changes initially.

How important is it?

Earnings results may either confirm growth prospects or raise concerns among investors.

Why Short Term?

Investor anticipation and subsequent reactions to Q4 results will drive immediate market behavior.

Related Companies

CRMDISRGABT
February 26, 2025 08:00 ET  | Source: InspireMD Inc. MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting the Events Section of the InspireMD investor relations website or by registering below. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on InspireMD’s website. Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1710071&tp_key=533cb06aa3 About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com. Investor Contact:Craig ShoreChief Financial OfficerInspireMD, Inc.888-776-6804craigs@inspiremd.com Webb CampbellGilmartin Group LLCWebb@gilmartinir.cominvestor-relations@inspiremd.com

Related News